Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Clin Infect Dis. 2010 Mar 1;50(S2):S54. doi: 10.1086/648966

Figure 6.

Figure 6

Schematic showing three recombinant proteins (five antigens) contained in a multicomponent meningococcal vaccine [96, 119]. Two of the components are fusion proteins (GNA 2132 fused with GNA 1030, and GNA 2091 fused with fHbp. The third component is recombinant NadA. N- and C- refer to the amino- and carboxy terminal portions, respectively, of the proteins. The scale bar represents 100 amino acids (AA). Of the five antigens, fHbp, GNA 2132 and NadA, shown in gray, were reported to be responsible for most of the SBA responses in mice [96]. In the vaccine formulation being investigated in phase 3 clinical trials, the three recombinant proteins are combined with a detergent-extracted OMV vaccine from group B strain NZ98/254.